Yoshiya Tanaka
Yoshiya Tanaka
Professor of Internal Medicine, University of Occupational and Environmental Health, Japan
Verified email at
Cited by
Cited by
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
H Umehara, K Okazaki, Y Masaki, M Kawano, M Yamamoto, T Saeki, ...
Modern rheumatology 22, 21-30, 2012
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ...
Arthritis & rheumatology 71 (9), 1400-1412, 2019
T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ
Y Tanaka, DH Adams, S Hubscher, H Hirano, U Siebenlist, S Shaw
Nature 361 (6407), 79-82, 1993
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
H Umehara, K Okazaki, Y Masaki, M Kawano, M Yamamoto, T Saeki, ...
Modern rheumatology 22 (1), 1-14, 2012
Lymphocyte interactions with endothelial cells
Y Shimizu, W Newman, Y Tanaka, S Shaw
Immunology today 13 (3), 106-112, 1992
Trial of anifrolumab in active systemic lupus erythematosus
EF Morand, R Furie, Y Tanaka, IN Bruce, AD Askanase, C Richez, ...
New England Journal of Medicine 382 (3), 211-221, 2020
Baricitinib versus placebo or adalimumab in rheumatoid arthritis
PC Taylor, EC Keystone, D Van Der Heijde, ME Weinblatt, ...
New England Journal of Medicine 376 (7), 652-662, 2017
The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4‐related disease
ZS Wallace, RP Naden, S Chari, H Choi, E Della‐Torre, JF Dicaire, ...
Arthritis & Rheumatology 72 (1), 7-19, 2020
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study
D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ...
Arthritis & Rheumatism 65 (3), 559-570, 2013
Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes
Y Tanaka, DH Adams, S Shaw
Immunology today 14 (3), 111-115, 1993
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
T Takeuchi, Y Tatsuki, Y Nogami, N Ishiguro, Y Tanaka, H Yamanaka, ...
Annals of the rheumatic diseases 67 (2), 189-194, 2008
Osteoblasts and osteoclasts in bone remodeling and inflammation
Y Tanaka, S Nakayamada, Y Okada
Current Drug Targets-Inflammation & Allergy 4 (3), 325-328, 2005
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion.
Y Tanaka, SM Albelda, KJ Horgan, GA Van Seventer, Y Shimizu, ...
The Journal of experimental medicine 176 (1), 245-253, 1992
Janus kinase inhibitors in autoimmune diseases
JJ O'Shea, A Kontzias, K Yamaoka, Y Tanaka, A Laurence
Annals of the rheumatic diseases 72 (suppl 2), ii111-ii115, 2013
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
DJ Wallace, RA Furie, Y Tanaka, KC Kalunian, M Mosca, MA Petri, ...
The Lancet 392 (10143), 222-231, 2018
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
M Tokunaga, K Saito, D Kawabata, Y Imura, T Fujii, S Nakayamada, ...
Annals of the rheumatic diseases 66 (4), 470-475, 2007
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
SB Cohen, Y Tanaka, X Mariette, JR Curtis, EB Lee, P Nash, KL Winthrop, ...
Annals of the rheumatic diseases 76 (7), 1253-1262, 2017
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
D Khanna, CJF Lin, DE Furst, J Goldin, G Kim, M Kuwana, Y Allanore, ...
The Lancet Respiratory Medicine 8 (10), 963-974, 2020
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y Tanaka, T Takeuchi, T Mimori, K Saito, M Nawata, H Kameda, T Nojima, ...
Annals of the rheumatic diseases 69 (7), 1286-1291, 2010
Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion …
GA van Seventer, W Newman, Y Shimizu, TB Nutman, Y Tanaka, ...
The Journal of experimental medicine 174 (4), 901-913, 1991
The system can't perform the operation now. Try again later.
Articles 1–20